Janney Montgomery Scott
ACAD icon

Janney Montgomery Scott’s Acadia Pharmaceuticals ACAD Stock Holding History

Janney Montgomery Scott’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,472
Closed -$522K – 3106
2026
Q1 		$522K Buy
+23,472
New +$561K ﹤0.01% 2017
2021
Q1 		– Sell
-4,060
Closed -$217K – 2165
2020
Q4 		$217K Buy
+4,060
New +$202K ﹤0.01% 2060

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Janney Montgomery Scott's ACAD Position: Q2 2026 in Review

Janney Montgomery Scott sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 23,472 shares — an estimated $522K sold.

Janney Montgomery Scott first reported a position in ACAD in Q4 2020 and held it in 2 quarters. The position peaked at $522K in Q1 2026. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Janney Montgomery Scott reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Janney Montgomery Scott sold 23,472 Acadia Pharmaceuticals shares in Q2 2026, an estimated $522K.
  • Janney Montgomery Scott first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Janney Montgomery Scott's Acadia Pharmaceuticals position peaked at $522K in Q1 2026.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.